Cargando…
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalido...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649824/ https://www.ncbi.nlm.nih.gov/pubmed/37958658 http://dx.doi.org/10.3390/ijms242115674 |
_version_ | 1785135639139713024 |
---|---|
author | Abramson, Hanley N. |
author_facet | Abramson, Hanley N. |
author_sort | Abramson, Hanley N. |
collection | PubMed |
description | The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of antimyeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bi- and multitargeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured. |
format | Online Article Text |
id | pubmed-10649824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106498242023-10-27 Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future Abramson, Hanley N. Int J Mol Sci Review The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of antimyeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bi- and multitargeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured. MDPI 2023-10-27 /pmc/articles/PMC10649824/ /pubmed/37958658 http://dx.doi.org/10.3390/ijms242115674 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Abramson, Hanley N. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title | Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title_full | Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title_fullStr | Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title_full_unstemmed | Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title_short | Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future |
title_sort | immunotherapy of multiple myeloma: current status as prologue to the future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649824/ https://www.ncbi.nlm.nih.gov/pubmed/37958658 http://dx.doi.org/10.3390/ijms242115674 |
work_keys_str_mv | AT abramsonhanleyn immunotherapyofmultiplemyelomacurrentstatusasprologuetothefuture |